In Part 1, Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) speaks to us about the mechanism of action of icosabutate, a novel engineered fatty acid currently under investigation in NASH.
He continues this conversation in Part 2 where we discuss the results from the interim analysis of the ICONA trial (NCT04052516).
His abstract entitled ‘Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial’ was presented at the International Liver Congress (ILC) 2021, 23-26 June.
Disclosures: Prof Arun Sanyal has acted as an advisor/board member for Gilead; a consultant for 89 BIO, Affimune, Albireo, Allergan, AMRA, Ardelyx, BASF, Birdrock, Boehringer Ingelheim, Bristol Myers Squibb, Chemomab, Conatus, Durect, Echosans, Enyo, Fractyl, Galectin, General Electric, Genfit, Gilead Hemoshear, Immuron, Indalo, Intercept, Janssen, Lilly, Malinckrodt, Merck, Nimbus, Novartis, Northsea, Novo Nordisk, Perspectum, Pfizer, Poxel, Salix, Sanofi, Second Genome, Servier, Takeda, Terns, Teva, Zydus; received grant/research support from Bristol-Myers Squibb, Conatus, Echosans, Galectin, Gilead, Lilly, Malinckrodt, Merck, Novartis, Novo Nordisk, Fractyl, Madrigal, Inventiva, Covance and Sequana; has stockholder/ownership interest (excluding diversified mutual funds) in Akarna, Durect, Exhalenz, Genfit, Hemoshear, Indalo, Tiziana; is PI for an ongoing trial sponsored by Genfit; has provided advice (no remuneration) to BASF, Galectin, Immuron and has received Royalties from Elsevier and UpToDate.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
